29 results
8-K
EX-10.116
ALTS
ALT5 Sigma Corp
30 Aug 24
ALT5 Sigma Appoints Peter Tassiopoulos as Chief Executive Officer
1:47pm
Term and relate in any way to the business or contemplated business, products, activities, research, or development of the Company or result from any
424B5
ALTS
ALT5 Sigma Corp
23 Aug 24
Prospectus supplement for primary offering
2:44pm
by extensive research and development efforts, rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. We … significantly greater financial resources, robust drug pipelines, established presence in the market, and expertise in research and development
424B5
ALTS
ALT5 Sigma Corp
21 Jun 24
Prospectus supplement for primary offering
5:20pm
industries are characterized by extensive research and development efforts, rapidly advancing technologies, intense competition, and a strong emphasis … , and expertise in research and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing
424B5
ALTS
ALT5 Sigma Corp
6 May 24
Prospectus supplement for primary offering
4:57pm
and pharmaceutical industries are characterized by extensive research and development efforts, rapidly advancing technologies, intense competition … in the market, and expertise in research and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement
424B5
l2z082ufct8pniis
22 Aug 23
Prospectus supplement for primary offering
12:54pm
8-K
EX-10.28
ah663waenfjhzj
31 May 22
Entry into a Material Definitive Agreement
8:52am
424B5
q8wjk02588p7
2 Feb 21
Prospectus supplement for primary offering
1:30pm
8-K
EX-99.1
gq3rnxckcz59h3qelwgz
3 Sep 20
Other Events
1:30pm
8-K
EX-10.1
dlvxv2sls4
7 Feb 20
JanOne strikes agreement with CoreRx, a leading cGMP contract manufacturer, for Phase 2b clinical formulation and development
12:00am
8-K
EX-10.1
gjlg8v3r
25 Nov 19
JanOne Acquires Worldwide, Exclusive License
8:00am